URINARY BLADDER NEOPLASMS

This phase 3 trial tests a new approach for people with muscle-invasive bladder cancer who cannot or choose not to have their bladder removed. Participants receive either a combination of TAR-200 (a drug placed directly into the bladder) plus cetrelimab (an immunotherapy), or sta…

This study tests two experimental treatments—TAR-200 (a drug placed inside the bladder) and cetrelimab (an immunotherapy injection)—alone or together, in people with high-risk bladder cancer that came back after BCG therapy. Participants are those who cannot or choose not to have…

This early-stage study tests a new treatment called TAR-210 in 5 Japanese patients with a type of bladder cancer that has specific genetic changes (FGFR mutations). The treatment is placed directly into the bladder to deliver the drug erdafitinib. The main goal is to see if it is…

This Phase 2 trial is testing whether combining two drugs, durvalumab (an immunotherapy) and olaparib (a targeted therapy), can help people with advanced bladder cancer who are not healthy enough for standard platinum chemotherapy. About 154 participants will receive either the d…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy can help people with muscle-invasive bladder cancer live longer without their cancer returning or spreading. About 520 participants who are eligible for non-surgical treatment will …

This study tests whether adding immunotherapy drugs (nivolumab, with or without BMS-986205) to standard chemotherapy before and after bladder cancer surgery helps more people achieve a complete response and live longer without the cancer returning. About 855 adults with muscle-in…

This study is testing a urine test called BladMetrix to see if it can detect bladder cancer returning after surgery. 500 adults with non-muscle invasive bladder cancer will provide urine samples during routine follow-up visits over 2 years. The test's accuracy will be compared to…